651 related articles for article (PubMed ID: 8837544)
1. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
Hodsman A; Adachi J; Olszynski W
CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.
CMAJ; 1996 Oct; 155(8):1113-33. PubMed ID: 8873639
[TBL] [Abstract][Full Text] [Related]
3. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
Murray TM; Ste-Marie LG
CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.
Siminoski K; Josse RG
CMAJ; 1996 Oct; 155(7):962-5. PubMed ID: 8837547
[TBL] [Abstract][Full Text] [Related]
5. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
Jones G; Hogan DB; Yendt E; Hanley DA
CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
[TBL] [Abstract][Full Text] [Related]
6. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
Josse RG
CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
[TBL] [Abstract][Full Text] [Related]
7. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis.
Murray TM
CMAJ; 1996 Oct; 155(7):935-9. PubMed ID: 8837543
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
11. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
12. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
13. [Use of bisphosphates in treatment of primary and secondary osteoporosis].
Olszyński WP
Pol Tyg Lek; 1995 Nov; 50(44-47):56-8. PubMed ID: 8643431
[TBL] [Abstract][Full Text] [Related]
14. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.
Woo T; Adachi JD
Best Pract Res Clin Rheumatol; 2001 Jul; 15(3):469-81. PubMed ID: 11485341
[TBL] [Abstract][Full Text] [Related]
15. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.
Brown JP; Josse RG;
CMAJ; 2002 Nov; 167(10 Suppl):S1-34. PubMed ID: 12427685
[TBL] [Abstract][Full Text] [Related]
16. Management of osteoporosis due to ovarian failure.
Eastell R
Med Pediatr Oncol; 2003 Sep; 41(3):222-7. PubMed ID: 12868123
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials with bisphosphonates.
Lombardi A; Santora AC
Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394
[TBL] [Abstract][Full Text] [Related]
18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
Blair MM; Carson DS; Barrington R
J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
